Pulmonary adverse events (AEs) represent a significant concern in the management of advanced non-small cell lung cancer (NSCLC), particularly with systemic therapies. The choice of first-line treatment impacts not only efficacy but also the safety profile. Recent data indicate that pembrolizumab monotherapy may offer a more favorable pulmonary safety profile compared to traditional platinum-based chemotherapy in this patient population.
The management of advanced non-small cell lung cancer (NSCLC) has evolved significantly with the introduction of immune checkpoint inhibitors. While these therapies have demonstrated superior efficacy in many settings, their distinct adverse event profiles, particularly immune-related adverse events (irAEs), necessitate careful consideration. Pulmonary irAEs, such as pneumonitis, are a known complication of PD-1/PD-L1 inhibitors, yet a comprehensive comparison of overall pulmonary adverse event burden between pembrolizumab and chemotherapy has been a focus of recent analysis.
Comparative Pulmonary Safety Profile
A pooled analysis of several pivotal trials, including KEYNOTE-024, KEYNOTE-042, and KEYNOTE-189, evaluated the incidence of pulmonary adverse events in patients with advanced NSCLC receiving first-line pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy, compared to chemotherapy alone. The analysis specifically focused on events classified as pulmonary, respiratory, thoracic, and mediastinal disorders.
The data revealed that pembrolizumab monotherapy was associated with a lower incidence of all-grade pulmonary adverse events compared to platinum-based chemotherapy. In patients receiving pembrolizumab monotherapy, the incidence of all-grade pulmonary AEs was 13.3%. In contrast, patients treated with platinum-based chemotherapy experienced an incidence of 23.9% for all-grade pulmonary AEs. This difference was statistically significant (p < 0.001).
When considering Grade 3-5 pulmonary adverse events, the rates were also lower with pembrolizumab monotherapy, at 2.8%, compared to 5.2% for chemotherapy (p < 0.01). The most common pulmonary adverse events reported in the chemotherapy arm included dyspnoea, cough, and pneumonia. While pneumonitis is a known irAE associated with pembrolizumab, its overall contribution to the total pulmonary AE burden was lower than the collective pulmonary events observed with chemotherapy.
The combination of pembrolizumab with chemotherapy also showed a numerically lower, though not statistically significant, rate of all-grade pulmonary AEs (20.1%) compared to chemotherapy alone (23.9%). For Grade 3-5 events, the combination arm reported 4.1%, compared to 5.2% for chemotherapy alone.
These findings suggest that while immune-related pneumonitis is a specific concern with pembrolizumab, the broader spectrum of pulmonary adverse events, including those related to myelosuppression and infection commonly seen with chemotherapy, contributes to a higher overall pulmonary toxicity burden in the chemotherapy arm. The mechanism for the observed reduction in pulmonary AEs with pembrolizumab monotherapy versus chemotherapy is multifactorial, likely involving differences in direct lung toxicity, immunosuppression leading to infection, and exacerbation of pre-existing lung conditions.
This analysis provides a clear signal that pembrolizumab monotherapy offers a pulmonary safety advantage over platinum-based chemotherapy in advanced NSCLC. For clinicians, this means that when selecting first-line therapy, particularly for patients with pre-existing pulmonary comorbidities such as COPD or interstitial lung disease, pembrolizumab may be the preferred option to mitigate the risk of exacerbating respiratory function. The data underscore the importance of moving beyond a singular focus on immune-related pneumonitis to consider the broader pulmonary toxicity profile of systemic anticancer treatments.
The pharmaceutical industry, particularly Merck, which markets pembrolizumab (Keytruda), will likely leverage these data to further differentiate their product in a competitive oncology market. While the efficacy of combination regimens remains compelling for many patients, this safety profile could influence treatment algorithms, especially in populations where minimizing pulmonary complications is paramount. It reinforces the trend towards more targeted and less toxic therapies, even as the definition of 'toxicity' expands to encompass a wider range of adverse events.
For patients, this translates to a potentially better quality of life during treatment, with fewer respiratory complications that can lead to hospitalizations or dose interruptions. While immune-related adverse events still require vigilance, the overall reduction in pulmonary distress could significantly impact their daily lives. It empowers shared decision-making, allowing patients and their physicians to weigh efficacy against a more nuanced understanding of treatment-related risks, particularly those affecting a vital organ system.
- The Pivot Pembrolizumab monotherapy is associated with a lower rate of pulmonary adverse events compared to platinum-based chemotherapy.
- The Data The incidence of all-grade pulmonary AEs was 13.3% with pembrolizumab versus 23.9% with chemotherapy.
- The Action Clinicians should consider pembrolizumab's pulmonary safety profile when selecting first-line therapy for advanced NSCLC patients, especially those with pre-existing pulmonary comorbidities.
ART-2026-416
06/26
Cite This Article
Team TLSFE. Pembrolizumab reduces pulmonary aes vs chemotherapy in nsclc. The Life Science Feed. Updated June 17, 2026. Accessed June 17, 2026. https://thelifesciencefeed.com/pulmonology/bronchiectasis/news/pembrolizumab-reduces-pulmonary-aes-vs-chemotherapy-in-nsclc.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
